Abstract
•There is a concern that renin-angiotensin-aldosterone system (RAAS) blockers increase susceptibility to coronavirus 2019 (COVID-19).•There no evidence that treatment with RAAS blockers worsens the course of COVID-19.•Discontinuation of RAAS blockers may exacerbate cardiovascular comorbidities.•RAAS blockers should be continued in patients with otherwise stable conditions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
